

Research Paper

Rosiglitazone Enhances Apolipoprotein M (Apom) Expression in Rat's Liver

Guanghua Luo¹, Yuehua Feng¹, Jun Zhang¹, Qinfeng Mu¹, Yuanping Shi¹, Li Qin¹, Lu Zheng¹, Maria Berggren-Söderlund³, Peter Nilsson-Ehle³, Xiaoying Zhang²✉ and Ning Xu³✉

1. Comprehensive Laboratory, the Third Affiliated Hospital of Soochow University, Changzhou 213003, P.R. China.
2. Department of Cardiothoracic Surgery, the Third Affiliated Hospital of Soochow University, Changzhou 213003, P.R. China;
3. Division of Clinical Chemistry and Pharmacology, Department of Laboratory Medicine, Lunds University, S-221 85 Lund, Sweden.

✉ Corresponding author: Xiaoying Zhang MD., Department of Cardiothoracic Surgery, the Third Affiliated Hospital of Soochow University, Changzhou 213003, P.R. China. Tel: +86 519 68871278; Fax: + 86 519 86621235; E-mail: zhangxy6689996@163.com and Ning Xu, MD, PhD., Division of Clinical Chemistry and Pharmacology, Department of Laboratory Medicine, Lunds University, Lund S-221 85, Sweden. Tel: +46 46 173487; Fax: + 46 46 130064; E-mail: ning.xu@med.lu.se.

© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (<http://creativecommons.org/licenses/by-nc-nd/3.0/>). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.

Received: 2013.12.10; Accepted: 2014.07.14; Published: 2014.07.29

Abstract

Apolipoprotein M (APOM) has been suggested as a vasculoprotective constituent of high density lipoprotein (HDL), which plays a crucial role behind the mechanism of HDL-mediated anti-atherosclerosis. Previous studies demonstrated that insulin resistance could associate with decreased APOM expressions. In agreement with our previous reports, here, we further confirmed that the insulin sensitivity was also reduced in rats treated with high concentrations of glucose; such effect could be reversed by administration of rosiglitazone, a peroxisome proliferator-activated receptor- γ (PPAR γ). The present study shows that *Apom* expression is significantly affected by either rosiglitazone or hyperglycemia alone without cross interaction with each other, which indicates that the pathway of *Apom* expression regulating by hyperglycemia might be differed from that by rosiglitazone. Further study indicated that hyperglycemia could significantly inhibit mRNA levels of *Lxrb* ($P=0.0002$), small heterodimer partner 1 (*Shp1*) ($P<0.0001$), liver receptor homologue-1 (*Lrh1*) ($P=0.0012$), ATP-binding cassette transporter 1 (*Abca1*) ($P=0.0012$) and *Pparb/d* ($P=0.0043$). Two-way ANOVA analysis demonstrated that the interactions between rosiglitazone and infusion of 25% glucose solution on *Shp1* ($P=0.0054$) and *Abca1* (4E, $P=0.0004$) mRNA expression was statistically significant. It is concluded that rosiglitazone could increase *Apom* expression, of which the detailed mechanism needs to be further investigated. The down-regulation of *Apom* by hyperglycemia might be mainly through decreasing expression of *Pparg* and followed by inhibiting *Lxrb* in rats.

Key words: Apolipoprotein M; Hyperglycemia; Insulin sensitivity; Liver receptor homologue-1; ATP-binding cassette transporter 1.

Introduction

Human apolipoprotein M (APOM) is mainly found in hepatocytes of the liver and tubular epithelial cells in kidney [1], and it could also been expressed weakly in the colorectal tissues [2]. The physiological roles of APOM were explored gradually during recent years. It has recently been documented that APOM can protect endothelium by delivering

sphingosine-1-phosphate (S1P) to the S1P1 receptor [3] and enhance the antioxidant effect of high density lipoprotein (HDL), in which the most abundant protein is APOA-I [4]. Also, it has been demonstrated that APOM is important for the formation of pre β -HDL and cholesterol efflux to HDL, which could attenuate atherosclerotic process [5].

We have previously reported that hepatic APOM levels were significantly decreased in hyperglycemic rats, and in cell cultures high concentrations of glucose inhibited APOM expression [6]. It was previously demonstrated that hyperglycemia could increase the flux of free fatty acids (FFAs) by accelerating lipolysis, which may induce or aggravate insulin resistance in the liver and muscle through altering the insulin signaling pathway [7, 8]. In light of evidence that mice with genetic defects of leptin (*ob/ob* mouse), exhibiting resistance to insulin, also showed significantly lower levels of Apom [9], we speculate that down-regulation of APOM expression by hyperglycemia may be associated with insulin resistance.

Rosiglitazone, a peroxisome proliferator-activated receptor- γ (PPAR γ) agonist used for the treatment of type 2 diabetes, is a potent insulin sensitizer that promotes glucose uptake by adipose tissue, skeletal muscle and liver [10-12]. Apart from improving insulin resistance, recent evidences demonstrated that rosiglitazone has multieffects, including attenuating airway inflammation by inhibiting the proliferation of effector T cells [13], reducing hippocampal neuronal damage [14], improving endothelial function [15], increasing cell surface GLUT4 level [16], preventing pulmonary fibrosis [17] and even preventing graft-versus-host disease [18]. However, it remains unknown whether rosiglitazone affects APOM *in vivo*. In the present study we examined the effects of rosiglitazone and hyperglycemia on Apom expression in a rat's models. According to our previous investigation showing that liver X receptor (LXR) [19, 20] and ATP-binding cassette transporter A1 (ABCA1) [21] could involve in the regulation of APOM expression. In the present study, we further examined the effects of rosiglitazone and hyperglycemia on expression of *Pparb/d* and genes of LXR signaling pathway including its target gene, *Abca1* in rat's models in order to find possible mechanism(s) of Apom regulation by rosiglitazone and hyperglycemia.

Materials and methods

Animal experiments. The experimental protocols were approved by the Animal Care and Use Committee of Soochow University, Suzhou, China. In general, each experimental group contained 6-8 adult male Sprague-Dawley rats (250-300g). Rats were commercially obtained from the Shanghai Slac Laboratory Animal Co., China or the Changzhou Cavens Laboratory Animal Co., China. Rats were kept in separate cages in a temperature-controlled (22°C) room with 12-hrs light-dark cycle and were provided with standard rodent chow and water *ad libitum*. The rats were acclimatized for one week before the experiments.

In the present study, all rats were pre-operated and two small catheters were placed in a jugular vein seven days before the liquid infusion. In brief, rats were anesthetized with 10% chloral hydrate (4ml/kg). Two catheters were placed in a jugular vein, one for infusion of 25% glucose solution (10ml \cdot kg $^{-1}$ \cdot h $^{-1}$ for 6 h, HuaYu Pharmaceutical Co.) or insulin solution (10mU \cdot kg $^{-1}$ \cdot min $^{-1}$ during HEC (hyperinsulinemic euglycemic clamp), Wanbang Biopharmaceuticals) and another for infusion of 20% glucose solution (during HEC). An additional catheter was placed in a carotid artery for blood sampling (also seven days before the experiments). The free ends of both catheters were attached to long segments of steel tubing and tunneled subcutaneously on the back of the neck. The catheters were flushed with isotonic saline containing 50 IU/ml heparin (Qianhong Bio-pharma Co.) and filled with a viscous solution of heparin (500 IU/ml) and 300 g/L polyvinyl pyrrolidone (PVP-10; Sigma) to prevent refluxing of blood into the catheter lumen.

When performing liquid infusions, the catheters were carefully connected to the infusion pumps (Smiths Medical). 25% glucose solution or insulin /20% glucose solution (during HEC) was infused for determining gene expressions or for assessing insulin sensitivity, respectively. Additionally, liquid was infused via tail vein in two parallel experiments which were performed to avoid the interference of the HEC test on gene expression. All the control rats were given 5% glucose solution. In the studies of rosiglitazone and/or infusion of 25% glucose solution on gene expressions, the rats were dosed daily with 0.25% (w/v) sodium carboxymethylcellulose (CMC, Sinopharm Chemical Reagent Co., Ltd) or rosiglitazone (Higher Biotech Co., Ltd, 4mg \cdot kg $^{-1}$, containing 0.25% CMC) via oral gavage for 4-5 days. The HEC technique was applied for assessing insulin sensitivity in rats (n=8 for each group) that were gavaged with 0.25% (w/v) CMC or rosiglitazone (dissolved in 0.25% CMC, at a concentration of 4mg \cdot kg $^{-1}$ \cdot d $^{-1}$) for 4 days, then infused with either 5% or 25% glucose solution intravenously for 5hrs. In another set of experiments without assessment of insulin sensitivity, rats (n=6) were gavaged with 0.25% (w/v) CMC or rosiglitazone (dissolved in 0.25% CMC, with the concentration of 4mg \cdot kg $^{-1}$ \cdot d $^{-1}$) for 5 days, then infused with either 5% or 25% glucose intravenously for 6hrs. After glucose infusion, blood samples and liver tissues were collected for plasma FFAs and Apom mRNA levels detection, respectively.

Reverse transcription and real-time RT-PCR. Total RNA in rats' tissues was extracted according to the manufacturer's instructions using a total RNA purification kit (Omega Bio-Tek). The quality of the RNA

samples was determined by the absorbance measurements at 260/280 nm. Using the first strand cDNA synthetic kit (Qiagen) according to the manufacturer's instructions, 2µg total RNA was reverse transcribed to cDNA. The mRNA levels of the target and reference genes were measured under real-time PCR using TaqMan technology. The PCR primer sets were designed according to the information of GenBank, as listed in Table 1. *B-actin* was used as reference genes. Relative standard curves were produced to compensate for the efficiency of the PCRs. Quantification of target genes mRNA levels was relative to *B-actin* mRNA level. The real-time PCR reaction for each gene was performed in a 25µL volume, in a glass capillary containing 0.1µL 100µM each primer and probe, 2µL cDNA, 2.5µL 10xbuffer, 1.5µL MgCl₂ (25mM), 0.5µL dNTP (10mmol/L), and Taq DNA polymerase 0.5µL. Thermal cycling conditions included the following steps: initial denaturation at 95 °C for 3 min, followed by 40 cycles at 95 °C for 5 sec and 60 °C for 15 sec (rat *Lxra*, 62 °C for 15 sec; rat *Apom*, 58°C for 12 sec; rat *B-actin*, 61°C for 10 sec). All PCRs were performed on the LightCycler (Roche, Switzerland) real-time PCR system.

Table 1: Sequences of primers and probes.

Gene	Primer/Probe	Sequence (5' to 3')
Rat <i>Apom</i>	Forward primer	acaagagaccccagagccc
	Reverse primer	tccatggtgggagccg
	Probe	FAM-acctgggctgtggtactttattgctgg-TAMRA
Rat <i>B-actin</i>	Forward primer	gccactgcccatcctct
	Reverse primer	ctggaagagagcctcgggg
	Probe	FAM-agctgctgacggctcaggctcactatc-TAMRA
Rat <i>Lxra</i>	Forward primer	ggagcagctacattgccata
	Reverse primer	cctctcttgacgttcagttctt
	Probe	FAM-tggccaactgccatggacaccta-TAMRA
Rat <i>Lxrb</i>	Forward primer	tgtcggggcagcggaac
	Reverse primer	gctcctcagaagcagcagc
	Probe	FAM-atggatgctctcatgcggcgca-TAMRA
Rat <i>Shp1</i>	Forward primer	cttcccttgaccacagccg
	Reverse primer	ctgactggcgatgtaggtcttagag
	Probe	FAM-acatcccagggtctgattacatcaatgc-TAMRA
Rat <i>Lrh1</i>	Forward primer	tgtcctgtgtgtggcgataaag
	Reverse primer	ggactgttcgcttaagaaacc
	Probe	FAM-tctgggtatcattacggtctctcactgt-TAMRA
Rat <i>Abca1</i>	Forward primer	gagaccaaccaggcaatccag
	Reverse primer	ttgatgagcgtgacttcggtt
	Probe	FAM-cgatatctcgattcatggagtgtgtaacc-TAMRA
Rat <i>Pparb/d</i>	Forward primer	gaagaaccgcaacaagtgtcagta
	Reverse primer	ccttcaaaagcggatagcgt
	Probe	FAM-cttccagaagtgcctggcctcggc-TAMRA

Determinations of FFAs. FFAs were determined with the nonesterified fatty acid (NEFA) colorimetric method (Applygen Technologies Inc, Beijing, China). Briefly, total plasma FFAs were extracted with chloroform: N-heptane: methanol (56:42:2), coupled with copper, reacted with color reagent and

measured with a colorimeter at 550 nm. The standard curve was produced using a series of dilution of palmitic acid.

Statistics. Data are expressed as means ± SEM. Statistical analyses were performed with the GraphPad Prism 6.0 software (GraphPad Software, Inc., San Diego, California, USA). Multiple comparisons were performed with one-way ANOVA, and comparisons between two groups were statistically evaluated by the unpaired *t*-test. Cross interaction was analyzed by two-way ANOVA. *P*-values less than 0.05 were considered significant.

Results

Effects of glucose and/or rosiglitazone on insulin sensitivity, hepatic *Apom* mRNA levels and plasma FFAs in rats

Both 25% glucose solution ($P<0.0001$) and rosiglitazone ($P<0.0001$) affect the glucose infusion rates (GIR) (Fig. 1A). Furthermore, the marked inhibition of GIR by 25% glucose could be reversed by administration of rosiglitazone ($P<0.001$) (Fig. 1A). Fig. 1B shows that hepatic *Apom* mRNA levels in rats were significantly decreased after infusion of 25% glucose solution ($P=0.0356$). Rosiglitazone significantly increased the hepatic *Apom* mRNA levels in groups with 5% ($P=0.0132$) or 25% ($P=0.0007$) glucose administration. However, the interaction of rosiglitazone and glucose on *Apom* mRNA expression was not statistically significant ($P=0.8981$). As shown in Fig. 1C, the plasma FFAs were clearly lower in rats infused with 25% glucose solution ($P=0.0005$), and rosiglitazone had no significant effect on plasma FFA levels in these rats ($P=0.9790$). Two-way ANOVA indicated that there was no interaction between rosiglitazone and glucose on plasma levels of FFAs ($P=0.2656$).

Effects of glucose and rosiglitazone on expression of genes of LXR signaling pathway, *Abca1* and *Pparb/d* mRNA expression in rat liver

As shown in figure 2, when rats infused with 25% glucose solution, hepatic mRNA levels of *Lxrb* were significantly inhibited ($P=0.0002$), and small heterodimer partner 1 (*Shp1*) ($P<0.0001$), liver receptor homologue-1 (*Lrh1*) ($P=0.0012$), ATP-binding cassette transporter 1 (*Abca1*) ($P=0.0012$) and *Pparb/d* ($P=0.0043$) were also significantly reduced, while rosiglitazone only decreased mRNA levels of *Shp1* ($P=0.0074$) and *Abca1* ($P=0.0171$) (Fig. 3).




Figure 1. Effects of glucose and rosiglitazone on insulin sensitivity, hepatic *Apom* mRNA levels and plasma FFAs. (A) GIR during hyperinsulinemic euglycemic clamp. (B) Hepatic *Apom* mRNA levels. (C) Effects of glucose and rosiglitazone on plasma FFAs. Data are presented as mean \pm SEM. * P < 0.05 and *** P < 0.001 vs. control.

Cross interactions between rosiglitazone and infusion of 25% glucose solution on genes of LXR signaling pathway, *Abca1* and *Pparb/d* mRNA expression

Two-way ANOVA analysis showed that the interactions between rosiglitazone and infusion of 25% glucose solution on *Shp1* (Fig. 4C, $P=0.0054$) and *Abca1* (Fig. 4E, $P=0.0004$) mRNA expression was statistically significant. And, the interactions on *Lxra* (Fig. 4A, $P=0.9844$), *Lxrb* (Fig. 4B, $P=0.0861$), *Lrh1* (Fig. 4D, $P=0.0592$) and *Pparb/d* (Fig. 4F, $P=0.0759$) were not statistically significant.

Discussion

In the present study, the rats in the control group were administrated with 5% glucose solution, to avoid the starving on normal physiological metabolic processes.

In agreement with previous reports [22-26], the insulin sensitivity was reduced in rats treated with




Figure 2. Effects of glucose on genes related to the LXR signaling pathway and mRNA level of *Pparb/d* in rat liver. Rats were infused with 5% glucose solution (controls, $n=6$) or 25% glucose solution ($n=6$) intravenously for 6hrs. Data are presented as means \pm SEM. ** P < 0.01 and *** P < 0.001 vs. controls.




Figure 3. Effects of rosiglitazone on genes related to the LXR signaling pathway and mRNA level of *Pparb/d* in rats' liver. Rats ($n=6$ for each group) were gavaged with 0.25% (w/v) CMC (Controls) or rosiglitazone (dissolved in 0.25% CMC, at a concentration of $4\text{mg kg}^{-1}\text{d}^{-1}$) for 5 days. Data are presented as means \pm SEM. * P < 0.05 and ** P < 0.01 vs. controls.

high concentrations of glucose and this effect could be reversed by rosiglitazone. The present study shows that *Apom* expression is also significantly affected by either rosiglitazone or hyperglycemia alone without cross interaction with each other, which suggests that the pathway of *Apom* expression regulated by hyperglycemia might be differed from that by rosiglitazone. Rosiglitazone is well documented, it acts through the PPAR γ pathway and alleviates insulin resistance by reducing uptake of free fatty acids as well as enhancing lipometabolism [27]. However, in the present study, plasma FFA levels did not increase as expected, but rather decreased plasma FFAs occurred when rats were infused with 25% glucose solution. It is possible that hyperglycemia can elicit insulin secretion [28] and insulin therefore suppress the fatty acid release through inhibiting lipolysis [29] in this experimental model. We previously reported that activation of neither PPAR α nor PPAR γ influenced *APOM* expression in HepG2 cells [30]. While interestingly, our present data demonstrated that activation of PPAR γ

by the rosiglitazone could up-regulate hepatic *Apom* expression in rats, which suggests that the signal pathway of PPAR γ on regulation of *Apom* expression might be much more complicated *in vivo* than *in vitro*, or perhaps, the difference between rat *Apom* gene and human *APOM* gene contributes to the regulation patterns of PPAR γ .

ABCA1 is an important member of the ATP-binding cassette-transporter family and is involved in the apoAI-mediated cholesterol efflux from macrophages [31]. PPAR γ activator i.e., rosiglitazone and troglitazone, could enhance *ABCA1* expression in primary human monocyte-derived macrophages [32], whereas ciglitazone had no effect in cultured human keratinocytes [33]. In this study, hepatic *Abca1* mRNA expression was down-regulated by either rosiglitazone or 25% glucose, but rosiglitazone could totally

reverse the hyperglycemia-induced down-regulation of *Abca1* expression, which demonstrated that down-regulation of *Abca1* expression induced by hyperglycemia, might be mediated via the PPAR γ pathway in rats.

Our previous study indicated that upregulation of *ABCA1* could elevate *APOM* expression. So *Abca1* down-regulated by rosiglitazone should suppress *Apom* in rat accordingly, but in present study, rosiglitazone significantly increased *Apom* expression, which suggested that upregulation of *Apom* induced by rosiglitazone might not be regulated through *Abca1*, which is possible that rosiglitazone or PPAR γ could bind to *Apom* promoter region directly regulating its expression. More detailed mechanism needs further investigation.




Figure 4. Cross interaction between rosiglitazone and glucose on target genes of LXR signaling pathway and *Pparb/d* mRNA expression. Rats (n=6 for each group) were gavaged with 0.25% (w/v) CMC or rosiglitazone (dissolved in 0.25% CMC, at a concentration of 4mg kg⁻¹ d⁻¹) for 5 days, then infused with 5% glucose solution (controls) or 25% glucose solution intravenously for 6 hrs. Data are presented as means \pm SEM. **P < 0.01 and ***P < 0.001 vs. controls.

To explore the mechanism of down-regulation of *Apom* by hyperglycemia, we analyzed mRNA expressions of genes related to the pathway of liver X receptor. Infusion of 25% glucose solution significantly decreased hepatic mRNA levels of *Lxrb*, *Shp1*, *Lrh1*, *Abca1* and *Pparb/d* in rats. We previously reported that palmitic acid-induced upregulation of *PPARB/D* expression could significantly inhibit *APOM* expression in HepG2 cells [34]. So by inference, inhibition of *Pparb/d* mediated by infusion of 25% glucose solution could elevate mRNA levels of *Apom*. However, the final result showed that infusion of 25% glucose solution significantly decreased *Apom* expression in rats. One reasonable explanation is that hyperglycemia might suppress *Apom* expression through multiple signal pathways *in vivo*. Venteclef, et al., have demonstrated that LRH1 could directly regulate human and mouse *Apom* transcription by binding to the LRH1 response element located in the proximal *APOM* promoter region, and bile acids suppressed *APOM* expression by inhibiting *LRH1* transcriptional activity [35]. We have demonstrated that activation of LXR triggers upregulation of *ABCA1* and subsequently increases *APOM* expression [21]. The results of present study showed that downregulation of genes (*Lxrb*, *Shp1*, *Lrh1*) of LXR signaling pathway and its target genes, *Abca1* by hyperglycemia could be inhibited by rosiglitazone, although the interactions between rosiglitazone and hyperglycemia on *Lxrb* (Fig. 4B, $P=0.0861$) and *Lrh1* (Fig. 4D, $P=0.0592$) did not reach the statistically significant levels. We therefore speculated that hyperglycemia suppresses *Apom* expression mainly via decreasing expression of *Pparg* and followed by inhibiting *Lxrb* in rat.

Acknowledgements

This research project was supported by the National Natural Science Foundation of China (NSFC) (81071414), the Natural Science Foundation of Jiangsu Province (BK2011245), a research grant from the Changzhou Science & Technology Bureau (CJ20122012) and Jiangsu Provincial 333 High-level Talents Cultivation Project (BRA2013062).

Competing Interests

The authors have declared that no competing interest exists.

References

- Zhang XY, Dong X, Zheng L, Luo GH, Liu YH, Ekstrom U, et al. Specific tissue expression and cellular localization of human apolipoprotein M as determined by in situ hybridization. *Acta histochemica*. 2003; 105: 67-72.
- Luo G, Zhang X, Mu Q, Chen L, Zheng L, Wei J, et al. Expression and localization of apolipoprotein M in human colorectal tissues. *Lipids in health and disease*. 2010; 9: 102.
- Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnstrom J, Sevvana M, et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. *Proc Natl Acad Sci U S A*. 2011; 108: 9613-8.
- Elsoe S, Ahnstrom J, Christoffersen C, Hoofnagle AN, Plomgaard P, Heinecke JW, et al. Apolipoprotein M binds oxidized phospholipids and increases the antioxidant effect of HDL. *Atherosclerosis*. 2012; 221: 91-7.
- Wolfrum C, Poy MN, Stoffel M. Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. *Nature medicine*. 2005; 11: 418-22.
- Zhang X, Jiang B, Luo G, Nilsson-Ehle P, Xu N. Hyperglycemia down-regulates apolipoprotein M expression in vivo and in vitro. *Biochimica et biophysica acta*. 2007; 1771: 879-82.
- Green A, Rumberger JM, Stuart CA, Ruhoff MS. Stimulation of lipolysis by tumor necrosis factor-alpha in 3T3-L1 adipocytes is glucose dependent: implications for long-term regulation of lipolysis. *Diabetes*. 2004; 53: 74-81.
- Delarue J, Magnan C. Free fatty acids and insulin resistance. *Curr Opin Clin Nutr Metab Care*. 2007; 10: 142-8.
- Xu N, Nilsson-Ehle P, Hurtig M, Ahren B. Both leptin and leptin-receptor are essential for apolipoprotein M expression in vivo. *Biochemical and biophysical research communications*. 2004; 321: 916-21.
- Le Bouter S, Rodriguez M, Guigal-Stephan N, Courtade-Gaiani S, Xuereb L, de Montron C, et al. Coordinate Transcriptomic and Metabolomic Effects of the Insulin Sensitizer Rosiglitazone on Fundamental Metabolic Pathways in Liver, Soleus Muscle, and Adipose Tissue in Diabetic db/db Mice. *PPAR Res*. 2010; 2010: 1-17.
- Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. *J Clin Endocrinol Metab*. 2001; 86: 280-8.
- Young PW, Cawthorne MA, Coyle PJ, Holder JC, Holman GD, Kozka IJ, et al. Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling. *Diabetes*. 1995; 44: 1087-92.
- Zhao Y, Huang Y, He J, Li C, Deng W, Ran X, et al. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates airway inflammation by inhibiting the proliferation of effector T cells in a murine model of neutrophilic asthma. *Immunol Lett*. 2014; 157: 9-15.
- Sayan-Ozacamak H, Ozacamak VH, Barut F, Jakubowska-Dogru E. Rosiglitazone treatment reduces hippocampal neuronal damage possibly through alleviating oxidative stress in chronic cerebral hypoperfusion. *Neurochem Int*. 2012; 61: 287-90.
- Gao XQ, Li HW, Ling X, Qiu YH, Gao Y, Zhang Y. Effect of rosiglitazone on rabbit model of myocardial ischemia-reperfusion injury. *Asian Pac J Trop Med*. 2013; 6: 228-31.
- Martinez L, Berenguer M, Bruce MC, Le Marchand-Brustel Y, Govers R. Rosiglitazone increases cell surface GLUT4 levels in 3T3-L1 adipocytes through an enhancement of endosomal recycling. *Biochem Pharmacol*. 2010; 79: 1300-9.
- Jin GY, Bok SM, Han YM, Chung MJ, Yoon KH, Kim SR, et al. Effectiveness of rosiglitazone on bleomycin-induced lung fibrosis: Assessed by micro-computed tomography and pathologic scores. *Eur J Radiol*. 2012; 81: 1901-6.
- Song EK, Yim JM, Yim JY, Song MY, Rho HW, Yim SK, et al. Rosiglitazone prevents graft-versus-host disease (GVHD). *Transpl Immunol*. 2012; 27: 128-37.
- Zhang X, Zhu Z, Luo G, Zheng L, Nilsson-Ehle P, Xu N. Liver X receptor agonist downregulates hepatic apoM expression in vivo and in vitro. *Biochemical and biophysical research communications*. 2008; 371: 114-7.
- Zhu C, Di D, Zhang X, Luo G, Wang Z, Wei J, et al. TO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells. *Lipids in health and disease*. 2011; 10: 199.
- Di D, Wang Z, Liu Y, Luo G, Shi Y, Berggren-Soderlund M, et al. ABCA1 upregulating apolipoprotein M expression mediates via the RXR/LXR pathway in HepG2 cells. *Biochemical and biophysical research communications*. 2012; 421: 152-6.
- Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, Kraegen EW. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucohomeostasis in the rat. *Diabetes*. 1994; 43: 1203-10.
- Eldershaw TP, Rattigan S, Cawthorne MA, Buckingham RE, Colquhoun EQ, Clark MG. Treatment with the thiazolidinedione (BRL 49653) decreases insulin resistance in obese Zucker hindlimb. *Horm Metab Res*. 1995; 27: 169-72.
- Kramer D, Shapiro R, Adler A, Bush E, Rondonone CM. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats. *Metabolism*. 2001; 50: 1294-300.
- Zhao Z, Lee YJ, Kim SK, Kim HJ, Shim WS, Ahn CW, et al. Rosiglitazone and fenofibrate improve insulin sensitivity of pre-diabetic OLETF rats by reducing malonyl-CoA levels in the liver and skeletal muscle. *Life Sci*. 2009; 84: 688-95.
- Gao W, Jusko WJ. Modeling disease progression and rosiglitazone intervention in type 2 diabetic Goto-Kakizaki rats. *J Pharmacol Exp Ther*. 2012; 341: 617-25.
- Song GY, Gao Y, Wang C, Hu SG, Wang J, Qu DM, et al. Rosiglitazone reduces fatty acid translocase and increases AMPK in skeletal muscle in aged rats: a possible mechanism to prevent high-fat-induced insulin resistance. *Chin Med J (Engl)*. 2010; 123: 2384-91.
- Chirieac DV, Chirieac LR, Corsetti JP, Cianci J, Sparks CE, Sparks JD. Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich

- lipoprotein and apoB production. *Am J Physiol Endocrinol Metab.* 2000; 279: E1003-11.
29. Boden G, Chen X, Desantis RA, Kendrick Z. Effects of insulin on fatty acid reesterification in healthy subjects. *Diabetes.* 1993; 42: 1588-93.
 30. Xu N, Ahren B, Jiang J, Nilsson-Ehle P. Down-regulation of apolipoprotein M expression is mediated by phosphatidylinositol 3-kinase in HepG2 cells. *Biochimica et biophysica acta.* 2006; 1761: 256-60.
 31. Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. *J Clin Invest.* 1999; 104: R25-31.
 32. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. *Nature medicine.* 2001; 7: 53-8.
 33. Jiang YJ, Lu B, Kim P, Elias PM, Feingold KR. Regulation of ABCA1 expression in human keratinocytes and murine epidermis. *Journal of lipid research.* 2006; 47: 2248-58.
 34. Luo G, Shi Y, Zhang J, Mu Q, Qin L, Zheng L, et al. Palmitic acid suppresses apolipoprotein M gene expression via the pathway of PPARbeta/delta in HepG2 cells. *Biochemical and biophysical research communications.* 2014; 445: 203-7.
 35. Venticlef N, Haroniti A, Tousaint JJ, Talianidis I, Delerive P. Regulation of anti-atherogenic apolipoprotein M gene expression by the orphan nuclear receptor LXR-1. *The Journal of biological chemistry.* 2008; 283: 3694-701.